At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 48 target
Drug / intervention
anti-CD19 CAR-NKbiological
Likely dose
Not stated in record
Key inclusion· 20
- ✓Age 18-75 years old
- ✓Histologically confirmed DLBCL, TFL, PMBCL, MCL, or other indolent B-cell NHL conversion type
- ✓Refractory or relapsed DLBCL after 2-line treatment or with disease progression within 12 months of autologous HSCT
- ✓Refractory or relapsed MCL resistant or intolerable to BTK inhibitors
Key exclusion· 15
- ✕History of allergy to any cell product ingredients
- ✕History of other malignancies
- ✕Prior Grade II-IV acute GvHD or extensive chronic GvHD
- ✕Current anti-GvHD treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05472558Phase 1RecruitingUpdate OverdueUpdated 15mo ago · Completion was 7mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
Second Affiliated Hospital, School of Medicine, Zhejiang University·interventional·Posted Jul 25, 2022·Updated Mar 4, 2025
In Brief
A Phase 1 clinical trial evaluating anti-CD19 CAR-NK for B-cell Non Hodgkin Lymphoma. Currently recruiting, targeting 48 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Non Hodgkin Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20232024202520262027
First PostedJul 2022
Enrollment StartJul 2022
Primary CompletionDec 2025
TodayJul 2026
Study CompletionDec 2026
First PostedJul 25, 2022
Enrollment StartJul 26, 2022
Primary CompletionDec 1, 2025
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 3.9 years ago
Interventions
anti-CD19 CAR-NKbiological
lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR